Summary
A phase I study with the combination of ifosfamide + carboplatin + etoposide (ICE) was conducted in patients with advanced non-small-cell lung cancer (NSCLC). Patients who had had previous therapy were given the following dosages: ifosfamide 2 g/m2 on days 1 to 3, carboplatin 75 mg/m2 on days 1 and 2, and etoposide 80 mg/m2 on days 1 and 2. In those with no previous therapy, carboplatin 75 mg/m2 was administered on days 1 to 3. In 15 treated patients, 3 objective responses were documented, all from the 7 patients with no prior therapy. The dose limiting toxicity was leucopenia. A phase II study is required to determine the exact activity of the combination in patients with advanced NSCLC.
Two patients with limited NSCLC were treated with high doses ICE (ifosfamide 6 g/m2 on day 1; carboplatin 400 mg/m2 on days 1 and 2, and etoposide 500 mg/m2 on days 1 and 2) and autologous bone marrow infusion followed by local therapy. Toxicity was acceptable. Responses were of short duration (10 months) and both patients died 13 and 15 months, respectively, after the start of therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ardizzoni A, Fusco V, Gulisano M, Pronzato P, Baracco F, et al. Etoposide, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer. Cancer Treatment Reports 71: 1311–1312, 1987
Bakowski MT, Crouch JC. Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treatment Reviews 10: 159–172, 1983
Klastersky J, Sculier JP, Dabouis G, Lacroix H, Donnadieu N, et al. A phase II study evaluating carboplatin plus etoposide in advanced non-small cell lung cancer. Abstract 916. Proceedings of the American Society of Clinical Oncology, 1989
Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. Journal of Clinical Oncology 4: 1780–1786, 1986
Kreisman H, Ginsberg S, Propert KJ, Richards F, Graziano S, et al. Carboplatin or iproplatin in advanced non-small cell lung cancer: a Cancer and Leukemia group B study. Cancer Treatment Reports 71: 1049–1052, 1987
Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. Cancer 50: 2751–2756, 1982
Morgan LR, Posey LE, Rainey J, Bickers, Ryan D, et al. Ifosfamide: a weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treatment Reports 65: 693–695, 1981
Sculier JP, Klastersky J. Progress in chemotherapy of non-small cell lung cancer. European Journal of Cancer and Clinical Oncology 20: 1329–1333, 1984
Thatcher N, Anderson H, Smith DB, Steward WP, Webb K, et al. Ifosfamide by bolus as treatment for advanced non-small cell lung cancer. Cancer Chemotherapy Pharmacology 18: S30–S33, 1986
Tueni E, Sculier JP, Klastersky J. Phase I study of a carboplatinetoposide combination in advanced thoracic cancer. European Journal of Cancer and Clinical Oncology 24: 963–967, 1988
Williams SF, Bitran JD, Hoffman PhC, Robin E, Fullem L, et al. High-dose multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer 63: 238–242, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sculier, J.P., Bron, D., Sergysels, R. et al. A Pilot Study with an Ifosfamide, Carboplatin and Etoposide Regimen (ICE) in Patients with Advanced Non-Small-Cell Lung Cancer. Drug Invest 2, 31–37 (1990). https://doi.org/10.1007/BF03259399
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259399